Difference between revisions of "Crizotinib (Xalkori)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
|||
| Line 31: | Line 31: | ||
[[Category:Mutation-specific medications]] | [[Category:Mutation-specific medications]] | ||
| − | + | ||
[[Category:ALK inhibitors]] | [[Category:ALK inhibitors]] | ||
[[Category:MET inhibitors]] | [[Category:MET inhibitors]] | ||
Revision as of 22:54, 28 February 2020
General information
Class/mechanism: Tyrosine kinase inhibitor; inhibits anaplastic lymphoma kinase (ALK), c-MET and subsequent expression of Hepatocyte Growth Factor Receptor (HGFR), and Recepteur d’Origine Nantais (RON). Inhibits activity of fusion proteins involving ALK, such as EML4-ALK and NPM-ALK.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Crizotinib (Xalkori) package insert pages 15-18[1]
- Crizotinib (Xalkori) patient drug information (Chemocare)[3]
- Crizotinib (Xalkori) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 8/26/2011: Initial accelerated approval for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
- 11/20/2013: FDA approval revised for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
- 3/11/2016: FDA approval expanded for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.
Also known as
- Code names: PF02341066, PF-02341066
- Brand name: Xalkori